1. Opportunities to enhance prescribing
efficiency for patients with diabetes in Abu
Dhabi without compromising care
Dr Mohammed Abuelkhair
Head, Pharma/Medicine & Medical Product
Regulation

2. G A S N O JC IE
O L A D BE TV S
 T eg a o teP am c v iln ea dR t n l e ic eU e
h o l fh h r a o ig a c n aio a M d in s
po rmo a H A is oid nif a dpo oeo t a du
rga f t A D t e ty n rm t pim l rg
pecib ga du e
rsr in n s.
 Srtg stosa dsric s r po id dt e c ua ete
t e ie, o l n ev e ae rv e o n o rg h
a ,
u eo e id n eb sdc ic l n c s efciv n s
s f v e c - ae l a a d o t f t e es
in - e
inom t nind c io m k ga o gh at c r po id r,
fr aio e is n a in m n e l ae rv es
h
c n u es n p lym k r.
o s m r a d oic a es
 T ea o tea d w s oa ayec r n t am n
h im fh u it a t n l z ur tr t e t
e e
a po c e a o gp t ns it T p 2d b tsT D )a d
p ra h s m n aie t w h y e ia ee ( 2 M n
c m aew hinen t n ltn ad . S c n l ass te
o p r it traio a s d rs e o dy ses h
a ,
e tn o d frn m n g m n a po c e/rsr in
xe t f if e t a a e e t p ra h s ecib g
e p
p t r a o gd frn fcit s
at n m n if e ta ilie.
e e

3. MT O S
EH D
 A d o 5 1rn o p t ns co s fcit s rain
u it f 6 a d m aie t a rs 3 a ilie t t g
e
T D p t ns v r y a.
2 M aie t o e 1 e r
1s e iais d b ts e tr
p c lt ia ee c ne,
1g v rm n ( K C d b ts e tr
o en e tS M ) ia ee c ne
1in e e d n piv t sco h s it
d p n e t r ae e tr o p a
 D t in ld de tn o p t n m n oin ( P l id ,
aa c e xe t f aie t o itr g B , ip s
u
H A c w ig trn lu cio , ec , oa g c m du s
b 1 , e h, e a fn t n t.) rl l e ic rg
y
pecib d w eh rh s pecib da m x a d ss
rsr e , h te tee rsr e t a im l o e
( IEg id n e b fr in uin , w eh r s l t am n
N C u a c ) eoe s l s h te in uin r t e t
e
d ly da din uintp .
ea e n s l y e

4. M JRFN IG
AO IDN S
Pecib g
rsr in
 H hu eo p tn poe tddu s c d g
ig s f ae t rtce rg in l in : u
 E p n iv m d ie rlaem d in se . m t r in
x e s e o if d ee s e ic e ( .g ef m
o
M / llz eM )v ru g n r s n adrlae
R gic id R es s e eic t d r ee s
a a
pe aaio s
rp rt n
 Gipin in ld gsa l t 5 m T IED I d s
l t s c in itgipin 0 g WC AL oe
u Y
 E p n iv in uin s c a in uingag e
x e s e s l s u h s s l lrin
 H hu eo gim p id
ig s f l e ir e
Q ait o c r
u ly f ae
 H A ce od din8 % t1 0 )o al aie t w h
b 1 rc re ( 3 o 0 % f lp t ns it
d b ts
ia ee
 L s ta 5 % o p t ns a arc re H A c f
es h n 0 f aie t h d e od d b 1 o <

5. M JRFN IG
AO IDN S
No of patients at each participating
facility
Types of medical intervention used to control diabetes

6. M JRFN IG
AO IDN S
HbA1c
Types of medical intervention used to control diabetes

7. M JRFN IG
AO IDN S
Prescribing of agents to control Trends in prescribing of oral anti-
hyperglycemia hyperglycemics.
Independent Government Specialist
hospital Hospital Center
(Private)
Metformin 39 % 85.5 % 87.6 %
Sulphonylurea 47 % 57.4 % 50.5 %
Glitazone 13 % 20.3 % 12.4 %
Prandial regulators 0 % 3.1 % 5.7 %
Gliptins 33% 64.5 % 61 %
Newer Agents (eg:
Exanetide) 0 % 7.4 % 3.8 %
Older anti 2% 0.8 % 1.0 %
-hyperglycemic agents
(eg:Acarbose)

8. M JRFN IG
AO IDN S
Trends in prescribing of generics Trends in prescribing sitagliptin

9. M JRFN IG
AO IDN S
Trends in prescribing Insulins

10. M JRFN IG
AO IDN S
Trends in prescribing sulphonylureas
Gliclazide modified release preparations may
be useful in patients who suffer with
hypoglycaemia with standard release
preparations. However the cost of the
modified release tablets is significantly higher
than standard tablets. In addition Glimepiride
is significantly more expensive than Gliclazide
There is no strong evidence to suggest
increased efficacy or lower incidence of side
effects from Glimepiride use.

11. M JRFN IG A D C N L S N
AO IDN S N O C U I SO
 W et aec s c udb rd c db
e sim t o t o l e e u e y
s
a po im tl 3 % tru hfl w ginen t n l
p rx aey 0 ho g ol in traio a
o
g id l e a drd c guilaio o e p n iv
u ein s n e u in tist n f x e s e
m d ie rlaepe aaio s
o if d ee s rp rt n
 C r c udas im rv db rg lr o itr go
ae o l l o po e y e ua m n oin f
H A c e es
b 1 lv l
 It d cio o P am c B n f M n g m n
nr u t n f h r a y e eit a a e e t
o
Ss m s o l as h l im rv a po r t s p
yt s h ud l ep po e p rpiae t
e o e
w ec r a drd c c s . I a d io , in rae
is ae n e u e o t n d it n ce s
s
IN pecib g h l m n o c m l n e a w l
N rsr in , ep o itr o pia c , s el
a m n o d ss f rg pecib d e . s t s
s o itr o e o du s rsr e , .g t ina